
A Breath of Fresh Air! Targeted Screening and Management of COPD in Primary Care Pearls for practice

Dr. Mohit Bhutani

Key Messages

- COPD is a debilitating, progressive and fatal respiratory disease. It is common and can be prevented. With proper management, there will be improved quality of life, a reduction in exacerbations and mortality.
- Tobacco exposure remains the number one cause for the development of COPD, other causes can be related to occupational exposure, indoor and outdoor pollution, family history of COPD (alpha 1-antitrypsin deficiency)
- As lung function declines, symptoms in COPD worsen. Dyspnea leads to deconditioning and further inactivity.
- The higher the dyspnea, the greater the risk for COPD exacerbations. Individuals are considered to be:
 - Low risk if they had 1 or less moderate exacerbation in the last year, and did not require and ED visit or hospitalization
 - **High risk** if they had 2 or more moderate or 1 or more severe exacerbation (requiring hospitalization or ED visit) in the last year
- Think COPD consider risk factors, their symptoms and screen using spirometry for diagnosis
- The Canadian Lung Health test increases pretest probability. If YES to any of the questions, patient should be sent for screening spirometry.
- Spirometry is the gold standard for diagnosis of COPD. A full Pulmonary Function Test is NOT always required.
- Classification by Impairment of lung function: GOLD Grades

Canadian Lung Health Test ¹		
ou are over 40 and smoke or used to smoke, you may already have COPD. Take this quid	ck test to	
symptoms of COPD:		
	Yes	No
Do you cough regularly?		
Do you cough up phlegm regularly?		
Do even simple chores make you short of breath?		
Do you wheeze when you exert yourself (exercise, go upstairs)?		
Do you get many colds, and do your colds usually last longer than your friends' colds?		








The Physician Learning Program & The Office of Lifelong Learning

A Breath of Fresh Air! Targeted Screening and Management of COPD in Primary Care Pearls for practice

Dr. Mohit Bhutani


There are 3 parameters to consider once a COPD diagnosis has been confirmed to ensure the right medication is given to the right patient at the right time:

- Assessment of their Dyspnea, using the mMRC score,
- Assessment of their Quality of Life (QoL) using the <u>CAT</u> score (reliable measure of the impact of COPD on a patient's health status, Score <10 low impact of COPD on health status)
- A patients future risk for COPD exacerbations.



- **Goals of therapy:** alleviate dyspnea, improve health status, prevent exacerbations of COPD, reduce mortality.
- Delays in optimal treatment is associated with a 43% increase risk of future COPD related hospitalization and ED visits as well as mortality.
- An optimized triple therapy regimen in high risk populations reduces mortality and the risk of exacerbations (32%)

For each item below, place a mark Be sure to only select one response		scribes you currently.	
EXAMPLE: I am very happy	0 🗶 2 3 4 5	I am very sad	Score
I never cough	012345	I cough all the time	
I have no phlegm (mucus) in my chest at all	012345	My chest is completely full of phlegm (mucus)	
My chest does not feel tight at all	012345	My chest feels very tight	
When I walk up a hill or one flight of stairs I am not breathless	012345	When I walk up a hill or one flight of stairs I am very breathless	
I am not limited doing any activities at home	012345	I am very limited doing activities at home	
I am confident leaving my home despite my lung condition	012345	I am not at all confident leaving my home because of my lung condition	
I sleep soundly	012345	I don't sleep soundly because of my lung condition	
I have lots of energy	012345	I have no energy at all	








A Breath of Fresh Air! Targeted Screening and Management of COPD in Primary Care Pearls for practice Dr. Mohit Bhutani

• COPD Management for the vast majority of patients in clinical practice reduce to:

- dual bronchodilators (LAMA & LABA)
- 2 single inhalers triple therapy (ICS/LAMA/LABA)
- Short acting Beta 2 agonist (SABA) for relief
- Single Inhaler Triple Therapy (SITT) is preferred over Multi-Inhaler Triple Therapy (MITT). The decision to switch should be part of a shared decision making with the patient.



Mild **Moderate and Severe** CAT <10 mMRC 1 CAT ≥10, mMRC ≥2 FEV,≥80% FEV, <80% Low Symptom Burden[†] Low AECOPD Risk** High AECOPD Risk** LAMA or LABA LAMA/LABA/ICS** IAMA/IABA* LAMA/LABA/ICS LAMA/LABA/ICS ORAL THERAPIES SABD prn

- Non- pharmacotherapy therapy is important as part of the management and prevention plan:
 - Self-management education; utilize Certified Respiratory Educators (42% reduction of exacerbations)
 - Smoking cessation
 - Vaccinations

Tkacz J et.al. int Chron Obstruct Pulmon Dis. 2022;17:329-342

 Pulmonary rehabilitation (55% reduction of exacerbations after hospitalization)

Resources:

l

- <u>2023 CTS COPD Pharmacotherapy Guidelines</u>
- Jones et.al. ERJ 2009; 34 (3): 648-54

- Canadian Lung Association
- Pulmonary Rehabilitation referral program

Consider using **MyL3Plan**, a free online tool developed by the Office of LIfelong Learning (L3) that can be used to meet and support the 3 activities/action plans required by the PPIP-CPSA and earn up to 36 Mainpro+ certified credits. by completing the following cycles:

- Practice-driven quality improvement using objective data (CQI)
- Personal Development (PD
- Standards of Practice Quality Improvement (SOP).

Join NAPCReN! NAPCReN data can help you identify patients with chronic diseases commonly seen in your practice. The Physician Learning Program has partnered with NAPCReN and will send you reports with individualized and comparison data on selected topics. This data can inform quality improvement cycles and help you advance your practice.





Find a previous webinar or learn about our upcoming events



<u>Learn more</u>

here!

